18F-FBPA as a tumor-specific probe of L-type amino acid transporter 1 (LAT1): a comparison study with 18F-FDG and 11C-Methionine PET
Creators
- 1. Osaka University Graduate School of Medicine, PET Molecular Imaging Center, Osaka (Japan)
- 2. Osaka University Graduate School of Medicine, Department of Nuclear Medicine and Tracer Kinetics, Osaka (Japan)
- 3. Osaka University Graduate School of Medicine, Department of Bio-system Pharmacology, Osaka (Japan)
- 4. Osaka University, Osaka University Graduate School of Medicine, Osaka University Hospital, Osaka (Japan)
- 5. Osaka University Graduate School of Medicine, Department of Molecular Imaging in Medicine, Osaka (Japan)
- 6. Osaka University, Immunology Frontier Research Center, Osaka (Japan)
Description
The purpose of this study was to evaluate the usefulness of L-4-borono-2-18F-fluoro-phenylalanine (18F-FBPA) as a tumor-specific probe, in comparison to 18F-FDG and 11C-methionine (Met), focusing on its transport selectivity by L-type amino acid transporter 1 (LAT1), which is highly upregulated in cancers. Cellular analyses of FBPA were performed to evaluate the transportability and Km value. PET studies were performed in rat xenograft models of C6 glioma (n = 12) and in rat models of turpentine oil-induced subcutaneous inflammation (n = 9). The kinetic parameters and uptake values on static PET images were compared using the one-tissue compartment model (K1, k2) and maximum standardized uptake value (SUVmax). The cellular analyses showed that FBPA had a lower affinity to a normal cell-type transporter LAT2 and induced less efflux through LAT2 among FBPA, Met, and BPA, while the efflux through LAT1 induced by FBPA was similar among the three compounds. The Km value of 18F-FBPA for LAT1 (196.8 ± 11.4 μM) was dramatically lower than that for LAT2 (2813.8 ± 574.5 μM), suggesting the higher selectivity of 18F-FBPA for LAT1. K1 and k2 values were significantly smaller in 18F-FBPA PET (K1 = 0.04 ± 0.01 ml/ccm/min and k2 = 0.07 ± 0.01 /min) as compared to 11C-Met PET (0.22 ± 0.09 and 0.52 ± 0.10, respectively) in inflammatory lesions. Static PET analysis based on the SUVmax showed significantly higher accumulation of 18F-FDG in the tumor and inflammatory lesions (7.2 ± 2.1 and 4.6 ± 0.63, respectively) as compared to both 18F-FBPA (3.2 ± 0.40 and 1.9 ± 0.19) and 11C-Met (3.4 ± 0.43 and 1.6 ± 0.11). No significant difference was observed between 18F-FBPA and 11C-Met in the static PET images. This study shows the utility of 18F-FBPA as a tumor-specific probe of LAT1 with low accumulation in the inflammatory lesions. (orig.)
Availability note (English)
Available from: http://dx.doi.org/10.1007/s00259-016-3487-1Additional details
Identifiers
Publishing Information
- Journal Title
- European Journal of Nuclear Medicine and Molecular Imaging
- Journal Volume
- 44
- Journal Issue
- 2
- Journal Page Range
- p. 321-331
- ISSN
- 1619-7070
INIS
- Country of Publication
- Germany
- Country of Input or Organization
- Germany
- INIS RN
- 48030199
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- BRAIN; CARBON 11; CELL CULTURES; COMPARATIVE EVALUATIONS; COMPUTERIZED TOMOGRAPHY; FLUORINE 18; GLIOMAS; IN VITRO; INFLAMMATION; INHIBITION; METHIONINE; NEUTRON CAPTURE THERAPY; ORGANIC FLUORINE COMPOUNDS; PHENYLALANINE; POSITRON COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; TURPENTINE; UPTAKE
- Descriptors DEC
- AMINO ACIDS; ANIMALS; AROMATICS; BETA DECAY RADIOISOTOPES; BETA-PLUS DECAY RADIOISOTOPES; BODY; CARBON ISOTOPES; CARBOXYLIC ACIDS; CENTRAL NERVOUS SYSTEM; COMPUTERIZED TOMOGRAPHY; DIAGNOSTIC TECHNIQUES; DISEASES; DRUGS; EMISSION COMPUTED TOMOGRAPHY; EVALUATION; EVEN-ODD NUCLEI; FLUORINE ISOTOPES; HOURS LIVING RADIOISOTOPES; ISOMERIC TRANSITION ISOTOPES; ISOTOPES; LABELLED COMPOUNDS; LIGHT NUCLEI; LIPOTROPIC FACTORS; MAMMALS; MATERIALS; MEDICINE; MINUTES LIVING RADIOISOTOPES; NANOSECONDS LIVING RADIOISOTOPES; NEOPLASMS; NERVOUS SYSTEM; NERVOUS SYSTEM DISEASES; NEUTRON THERAPY; NONAQUEOUS SOLVENTS; NUCLEAR MEDICINE; NUCLEI; ODD-ODD NUCLEI; ORGANIC ACIDS; ORGANIC COMPOUNDS; ORGANIC HALOGEN COMPOUNDS; ORGANIC SOLVENTS; ORGANIC SULFUR COMPOUNDS; ORGANS; PATHOLOGICAL CHANGES; RADIOACTIVE MATERIALS; RADIOISOTOPES; RADIOLOGY; RADIOTHERAPY; RODENTS; SOLVENTS; SYMPTOMS; TERPENES; THERAPY; TOMOGRAPHY; VERTEBRATES